Investigating how a specific protein affects resistance to HER2 therapy in breast cancer
Official title: The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer
Funded at Roswell Park Cancer Institute Corp · NIH-11049174 · Data updated 2026-11-12
This study is looking at how a protein called USP27X affects breast cancer cells' ability to resist treatments that target HER2, and it hopes to find ways to make these treatments work better for patients with HER2-positive breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | April 26, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $437,784 |
| NIH project number | 5R01CA272771-03 |
| Project ID | NIH-11049174 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with HER2-positive breast cancer who have shown resistance to standard HER2-targeting therapies.
✕Less likely to help
Patients with HER2-negative breast cancer or those who have not undergone HER2-targeted therapies may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called USP27X in the resistance of breast cancer cells to HER2-targeting therapies. It aims to explore how overexpression of another protein, Cyclin D1, contributes to this resistance and how targeting USP27X could enhance the effectiveness of existing treatments. By studying the mechanisms behind these interactions, the research seeks to identify new therapeutic strategies that could improve patient outcomes. Patients may benefit from insights that could lead to more effective treatments for HER2-positive breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with HER2 therapy-resistant breast cancer.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Atanassov, Boyko S — Roswell Park Cancer Institute Corp
- Study coordinator: Atanassov, Boyko S
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.